Last reviewed · How we verify

NCT06159556

Effects of Peanuts on Immunity and Cardiometabolic Risk Factors

Completed NA Last updated 2 October 2024
What this trial tests

NA trial testing Peanut intake in Immune Response in 80 participants. Completed in 26 September 2024.

Timeline
31 January 2024
Primary endpoint
26 September 2024
26 September 2024

Quick facts

Lead sponsorLoma Linda University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment80
Start date31 January 2024
Primary completion26 September 2024
Estimated completion26 September 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Loma Linda University

Who can join

Adults 18 to 70, any sex, with Immune Response or Cardiometabolic Risk Factors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the proposed study is two-fold: to determine whether the intake of peanuts (a) enhances immune function and (b) produces a desirable impact on selected cardiometabolic biomarkers and risk factors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Immune Response

Currently open trials in the same condition.

Other Loma Linda University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06159556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing